<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03377881</url>
  </required_header>
  <id_info>
    <org_study_id>STHLM3MR-2</org_study_id>
    <nct_id>NCT03377881</nct_id>
  </id_info>
  <brief_title>Prostate Cancer Detection Using the Stockholm3 Test and MR/Fusion Biopsies</brief_title>
  <acronym>STHLM3MR-2</acronym>
  <official_title>STHLM3 MR Phase 2: A New Diagnostic Chain for Prostate Cancer Detection Using the Stockholm3 Test and MR/Fusion Biopsies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      STHLM3-MR Phase 2 is a study comparing traditional prostate cancer detection using PSA and&#xD;
      systematic biopsies with the improved pipeline for prostate cancer detection using the STHLM3&#xD;
      test and targeted biopsies in a screening context.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overarching strategy of the STHLM3-MR/Fusion projects are to study an improved diagnostic&#xD;
      pipeline including an improved blood-based test for identification of men with increased risk&#xD;
      of prostate cancer and use of MRI to select men for diagnostic workup with targeted prostate&#xD;
      biopsies. The aim is to increase the specificity in early detection of prostate cancer&#xD;
      without decreasing the sensitivity of aggressive prostate cancers.&#xD;
&#xD;
      The primary endpoints are the number of performed biopsies, the number of performed MRI and&#xD;
      the number of detected high-risk prostate cancers. Secondary endpoints include the number of&#xD;
      low risk prostate cancers diagnosed and the proportion of patients with up-or downgraded&#xD;
      disease after assessment of prostatectomy specimen. Additional aims include to assess the&#xD;
      health economic consequences and development of automated image-analysis.&#xD;
&#xD;
      The STHLM3-MR project is performed in two separate phases, analyzed separately. STHLM3-MR&#xD;
      Phase 1 closed inclusion 2017-06-01. All participants underwent target and systematic&#xD;
      biopsies together with STHLM3 test analysis. The study is constitutes a current practice&#xD;
      cohort and levels of the STHLM3 test were not used for selecting participants.&#xD;
&#xD;
      STHLM3-MR Phase 2 is a study comparing traditional prostate cancer detection using PSA and&#xD;
      systematic biopsies with the improved pipeline for prostate cancer detection using the STHLM3&#xD;
      test and targeted biopsies in a screening context.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 4, 2018</start_date>
  <completion_date type="Actual">December 10, 2020</completion_date>
  <primary_completion_date type="Actual">December 10, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two-step design with a first step using paired design for blood-analysis and a second step using randomisation between prostate biopsy strategy.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of detected cancers characterized as Gleason Score ≥7 on evaluation of biopsy specimen</measure>
    <time_frame>At 2 months after study closure (last included biopsy procedure)</time_frame>
    <description>Cancers detected by pathological evaluation of biopsy specimen collected from the respective study arm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of detected cancer with Gleason Score 6</measure>
    <time_frame>At 2 months after study closure (last included biopsy procedure)</time_frame>
    <description>Cancers detected by pathological evaluation of biopsy specimen collected from the respective study arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of performed biopsy procedures in the study arms</measure>
    <time_frame>At 2 months after study closure (last included biopsy procedure)</time_frame>
    <description>Number of performed prostate biopsy procedures counted per study arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of performed MRI in the study arms</measure>
    <time_frame>At 2 months after study closure (last included biopsy procedure)</time_frame>
    <description>Number of performed prostate MRI procedures counted per study arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of infectious complications</measure>
    <time_frame>Questionnaire collection finalised within 2months after last biopsy procedure in study</time_frame>
    <description>As assessed by questionnaire within 2 month after biopsy procedure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12750</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Traditional</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The traditional/control arm consists of PSA testing and if PSA&gt;3ng/ml a systematic biopsy of the prostate is performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>STHLM3+MRI/Fusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental arm consists of a Stockholm3 bloodiest and if elevated, an MRI is recommended with targeted biopsies to prostate lesions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MRI/Fusion biopsies</intervention_name>
    <description>The intervention in the experimental arm is an MRI with targeted biopsies using fusion technique to prostate lesions.</description>
    <arm_group_label>STHLM3+MRI/Fusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Systematic biopsies</intervention_name>
    <description>The intervention in the control arm is traditional systematic biopsies of the prostate.</description>
    <arm_group_label>Traditional</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Permanent postal address in Stockholm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Severe illnesses such as metastatic cancers, severe cardio-vascular disease or&#xD;
             dementia&#xD;
&#xD;
               -  Contraindications for magnetic resonance imaging (MRI) eg pacemaker, magnetic&#xD;
                  cerebral clips, cochlear implants or severe claustrophobia.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tobias Nordström, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Capio St Görans Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GHP Odenplan Urology</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sophiahemmet Urology</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://sthlm3.se</url>
    <description>Study homepage</description>
  </link>
  <reference>
    <citation>Nordström T, Picker W, Aly M, Jäderling F, Adolfsson J, Ström P, Haug ES, Eklund M, Carlsson S, Grönberg H. Detection of Prostate Cancer Using a Multistep Approach with Prostate-specific Antigen, the Stockholm 3 Test, and Targeted Biopsies: The STHLM3 MRI Project. Eur Urol Focus. 2017 Dec;3(6):526-528. doi: 10.1016/j.euf.2017.01.014. Epub 2017 Mar 28.</citation>
    <PMID>28753850</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 28, 2017</study_first_submitted>
  <study_first_submitted_qc>December 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2017</study_first_posted>
  <last_update_submitted>December 10, 2020</last_update_submitted>
  <last_update_submitted_qc>December 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Tobias Nordström</investigator_full_name>
    <investigator_title>Urologist PhD Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

